Program
Tetanus Toxoid
Also written as “Tetanus Toxoid (Adsorbed)” and “Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine”.
Its studies are mostly in Tetanus, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Minhai Biotechnology | 10 open or running | phase 3since Jul 28, 2026 | Jul 28, 2026 | none ahead |
| Sanofi | 10 open or running | phase 4since Sep 20, 2011 | Sep 20, 2011 | none ahead |
| Sinovac Biotech | 10 open or running | phase 2since Apr 15, 2025 | Apr 15, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 20, 2011First study: phase 4 study in TetanusNew to SanofiSanofi · NCT01439165 · 1,330 enrolled · United States, Canada
- Apr 15, 2025Sinovac Biotech's first study: phase 2 study in TetanusNew to Sinovac BiotechSinovac Biotech · NCT06939777 · 255 enrolled · China
- Jul 28, 2026Beijing Minhai Biotechnology's first study: phase 3 study in TetanusNew to Beijing Minhai BiotechnologyBeijing Minhai Biotechnology · NCT07740733 · 1,240 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Tetanus toxoid vaccine antigen”ChEMBL 37, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07740733Tetanus · China | 3 | Completed | Beijing Minhai Biotechnology | Dec 23, 2024 | 1,240 |
| NCT06939777Tetanus · China | 2 | Completed | Sinovac Biotech | Dec 8, 2025 | 255 |
| NCT01439165Tetanus · United States, Canada | 4 | Completed | Sanofi | Dec 2015 | 1,330 |
How it is read
Names in the registry
- “Tetanus Toxoid (Adsorbed)”, 2 entries
- “Tetanus Toxoid”, 1 entry
- “Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.